Clinical endpoint: Latest News, Top Stories & Analysis

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

December 16, 2021December 15, 2021 - by MyChesCo

MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis …

Products and Services / Research

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab

March 20, 2021March 20, 2021 - by MyChesCo

EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory …